- Get in Touch with Us
Last Updated: Apr 25, 2025 | Study Period: 2024-2030
Men who suffer from erectile dysfunction, also known as sexual impotence, are treated with an injection of alprostadil.
It is one of a class of drugs called vasodilators, which work by making blood vessels grow. Men who do not suffer from erectile dysfunction should not take Alprostadil as a sexual aid.
Alprostadil can be used alone or in conjunction with other medical tests to diagnose erectile dysfunction that may be brought on by issues with the penis' nerves or blood vessels. This medication is accessible just with your PCP's remedy.
The Global Alprostadil injection market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
The US Food and Drug Administration has given Upjohn permission to sell Caverject Injection (alprostadil sterile powder) to diagnose and treat male erectile dysfunction resulting from neurologic, vascular, psychological, or mixed causes.
Although other drugs have been used off-label for many years, this product is the first prescription medication for erectile dysfunction to be approved in the United States (see also pages 26-27).
Caverject is injected into the corpus cavernosum with a small needle.
Caverject can be self-administered by the patient at will after Upjohn suggests that patients selected for treatment receive initial injections from medically trained personnel to determine the optimal dosing.
The company says the maximum dose shouldn't be more than 60mcg.It comes in vials of 10mcg and 20mcg.
The medication increases blood flow to the penis by relaxing smooth muscle.
It is derived from the vasoactive agent prostaglandin E1, which has been used to treat conditions like congenital heart defects in premature babies for a long time (Upjohn already sells the drug under the brand name Prostin VR Pediatric for keeping arteries open during neonatal heart surgery).
Papaverine, whether administered with or without phentolamine, is a common component of conventional intracavernosal injection therapy. In addition, papaverine acts as a smooth muscle relaxant.
The product will be promoted to general practitioners and other health care providers. Upjohn likewise noticed that the item might be a valuable assistant to other symptomatic tests in the determination of erectile brokenness.
| Sl no | Topic |
| 1 | Market Segmentation |
| 2 | Scope of the report |
| 3 | Abbreviations |
| 4 | Research Methodology |
| 5 | Executive Summary |
| 6 | Introduction |
| 7 | Insights from Industry stakeholders |
| 8 | Cost breakdown of Product by sub-components and average profit margin |
| 9 | Disruptive innovation in the Industry |
| 10 | Technology trends in the Industry |
| 11 | Consumer trends in the industry |
| 12 | Recent Production Milestones |
| 13 | Component Manufacturing in US, EU and China |
| 14 | COVID-19 impact on overall market |
| 15 | COVID-19 impact on Production of components |
| 16 | COVID-19 impact on Point of sale |
| 17 | Market Segmentation, Dynamics and Forecast by Geography, 2024-2030 |
| 18 | Market Segmentation, Dynamics and Forecast by Product Type, 2024-2030 |
| 19 | Market Segmentation, Dynamics and Forecast by Application, 2024-2030 |
| 20 | Market Segmentation, Dynamics and Forecast by End use, 2024-2030 |
| 21 | Product installation rate by OEM, 2023 |
| 22 | Incline/Decline in Average B-2-B selling price in past 5 years |
| 23 | Competition from substitute products |
| 24 | Gross margin and average profitability of suppliers |
| 25 | New product development in past 12 months |
| 26 | M&A in past 12 months |
| 27 | Growth strategy of leading players |
| 28 | Market share of vendors, 2023 |
| 29 | Company Profiles |
| 30 | Unmet needs and opportunity for new suppliers |
| 31 | Conclusion |
| 32 | Appendix |
© 2017-2025 Mobility Foresights Admin Pvt Ltd. All rights reserved.